Percutaneous transluminal angioplasty and stent implantation for aortic coarctation in haemophilia A patient with high‐titre factor <scp>VIII</scp> inhibitors

Giuffrida, G; Lombardo, R.; Parrinello, Nunziatina Laura; Cingari, Maria Rocca; Francesco, Ernesto Di; Triolo, Anna; Ussia, Gianpaolo; Arcidiacono, A; Scandura, Salvatore; Raimondo, Francesco Di

doi:10.1111/hae.12433

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 24 reports were identified which provided information relevant to the issue of major surgery in patients with haemophilia and inhibitors. These included five prospective studies and 19 retrospective case series (level of evidence III to IV). Ten studies evaluated the efficacy of rFVIIa in a total of 67 procedures , nine evaluated aPCC in a total of 72 procedures , and five evaluated both agents in a total of 63 procedures .…”

Section: Resultsmentioning

confidence: 99%

Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors

Mingot‐Castellano

Álvarez‐Román

López-Fernández

et al. 2016

European J of Haematology

View full text Add to dashboard Cite

Introduction: Patients with severe haemophilia and inhibitors against factor VIII who require surgery need a prophylactic approach to prevent bleeding complications. Scientific evidence to decide the best prophylactic treatment is very limited and mainly based on retrospective or case series. Aims: To develop evidence-and expert opinion-based guidelines for prophylactic therapy for patients with haemophilia and inhibitors undergoing surgery. Methods: A panel of nine Spanish haematologists undertook a systematic review of the literature and selected publications providing relevant information regarding the prophylactic management of patients with haemophilia and inhibitors undergoing dental extraction, minor surgery or major surgery. Results: Although evidence is very limited, the panel considers that it seems advisable that prophylaxis should be given in most cases with a bypassing agent (aPCC or rFVIIa) and should start immediately before minor or major surgery. Patients should be closely monitored to enable dose/product modification as needed. Conclusion: It is necessary to communicate clinical experience in a detailed way in order to ensure optimal schemes of prophylaxis for patients with haemophilia and inhibitors. Development of objective outcomes to evaluate efficacy is crucial.

show abstract